Commentary: Absolute and relative contraindications to pegylated-interferon or ribavirin in the US general patient population with chronic hepatitis C - Authors' reply

A. H. Talal, J. Lafleur, R. S. Hoop, P. Pandya, P. Martin, I. M. Jacobson, J. Han, E. J. Korner

Research output: Contribution to journalComment/debate

Original languageEnglish (US)
Pages (from-to)554-555
Number of pages2
JournalAlimentary Pharmacology and Therapeutics
Volume38
Issue number5
DOIs
StatePublished - Sep 1 2013

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology
  • Pharmacology (medical)

Cite this